Atrix Laboratories has received US FDA 510(k) clearance to market its Atrisorb FreeFlow guided tissue regeneration (GTR) barrier incorporated with the antibiotic doxycycline. The antibiotic, which inhibits bacterial growth, is released over a period of seven days following surgery, said the Fort Collins, Colorado-based company. An earlier version of Atrisorb without the antibiotic component was cleared for sale in the US four years ago (see Clinica No 699, p19). GTRs are used during periodontal surgery to help regenerate bone and tissues destroyed by periodontal disease.
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?